NCT06615921

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and Its Effectiveness in Patients With Post-Transplant Cytomegalovirus Infection/Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 265 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim of this study is to check how effective the treatment with Maribavir has been to remove the CMV viruses from the blood of an adult person with CMV infection after a transplant. Other aims are to learn more about how maribavir is used in normal clinical routine, study the profiles of adults treated with maribavir, and what other treatments have been given, and describe healthcare resources used for CMV management. Only data already available in the medical records of the participants will be reviewed and collected during this study.

Detailed description

This study will include two main periods of retrospective data collection from medical charts: the pre-index period and the post-index period. The index date is defined as the date of initiation of maribavir dosing, as documented in the medical records. The pre-index period covers the time from the transplant date to the index event, while the post-index period starts at the index event and ends at the date of chart abstraction, death, or loss to follow-up, whichever comes first.

Conditions

• Cytomegalovirus (CMV)

Interventions

Type	Name	Description
OTHER	No Intervention	This is a non-interventional study.

Timeline

• Start date: 2024-10-14
• Primary completion: 2025-07-04
• Completion: 2025-07-04
• First posted: 2024-09-27
• Last updated: 2025-08-08

Locations

45 sites across 10 countries: Austria, Denmark, France, Germany, Italy, Netherlands, Serbia, Spain, Switzerland, United Kingdom